"Thiazolidinediones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).
Descriptor ID |
D045162
|
MeSH Number(s) |
D02.886.675.933 D03.383.129.708.933
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazolidinediones".
Below are MeSH descriptors whose meaning is more specific than "Thiazolidinediones".
This graph shows the total number of publications written about "Thiazolidinediones" by people in this website by year, and whether "Thiazolidinediones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 3 | 0 | 3 |
2005 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2007 | 2 | 0 | 2 |
2008 | 2 | 0 | 2 |
2009 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiazolidinediones" by people in Profiles.
-
The "Cost-Effective" beneficial effect of pioglitazone on cardiovascular disease. Diabetes Res Clin Pract. 2020 07; 165:108223.
-
An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018 Jan; 135:102-110.
-
Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. J Diabetes Complications. 2016 08; 30(6):981-5.
-
Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population. J Diabetes Complications. 2015 Nov-Dec; 29(8):1248-52.
-
Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. Endocr Pract. 2011 Sep-Oct; 17(5):691-8.
-
Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res. 2011; 34(1):20-33.
-
Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant. 2009 Aug; 24(8):2384-91.
-
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008 Jan; 31(1):173-5.
-
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia. 2008 Jan; 51(1):8-11.
-
Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone. BJU Int. 2007 Oct; 100(4):867-74.